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Abstract
Background: Campylobacter jejuni is the most prevalent cause of bacterial gastroenteritis worldwide. Despite the significant
health burden this infection presents, molecular understanding of C. jejuni-mediated disease pathogenesis remains poorly
defined. Here, we report the characterisation of the early, innate immune response to C. jejuni using an ex-vivo human gut
model of infection. Secondly, impact of bacterial-driven dendritic cell activation on T-cell mediated immunity was also
sought.
Methodology: Healthy, control paediatric terminal ileum or colonic biopsy tissue was infected with C. jejuni for 8–12 hours.
Bacterial colonisation was followed by confocal microscopy and mucosal innate immune responses measured by ELISA.
Marked induction of IFNc with modest increase in IL-22 and IL-17A was noted. Increased mucosal IL-12, IL-23, IL-1b and IL-6
were indicative of a cytokine milieu that may modulate subsequent T-cell mediated immunity. C. jejuni-driven human
monocyte-derived dendritic cell activation was followed by analyses of T cell immune responses utilising flow cytometry
and ELISA. Significant increase in Th-17, Th-1 and Th-17/Th-1 double-positive cells and corresponding cytokines was
observed. The ability of IFNc, IL-22 and IL-17 cytokines to exert host defence via modulation of C. jejuni adhesion and
invasion to intestinal epithelia was measured by standard gentamicin protection assay.
Conclusions: Both innate and adaptive T cell-immunity to C. jejuni infection led to the release of IFNc, IL-22 and IL-17A;
suggesting a critical role for this cytokine triad in establishing host anti-microbial immunity during the acute and effectors
phase of infection. In addition, to their known anti-microbial functions; IL-17A and IL-17F reduced the number of
intracellular C. jejuni in intestinal epithelia, highlighting a novel aspect of how IL-17 family members may contribute to
protective immunity against C. jejuni.
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Introduction
Campylobacter jejuni is one of the commonest causative agents of
acute bacterial gastroenteritis worldwide [1,2]. Infection results in
clinical symptoms that can range from mild diarrhoea to severe
inflammatory enteritis, infection may also precipitate Inflamma-
tory Bowel Disease (IBD) in genetically predisposed individuals
[3]. The majority of C. jejuni infections are self-limiting, yet
intriguingly, when compared to other well-recognised enteric
pathogens (e.g. Shigella, Salmonella), it is C. jejuni infection that
precedes to a much greater extent in those who succumb to
autoimmune complications such as ulcerative colitis and Guillain-
Barre´ Syndrome (GBS) [4]. The health burden of C. jejuni-
associated pathologies, in particular the significant link to
morbidity in children in the developing world [5], along with
emergence of antibiotic-resistant clinical isolates [6], are all factors
driving current impetus for gaining further insight into C. jejuni-
mediated disease pathogenesis [1,2,7].
The study of pathogenesis is currently severely hampered by the
lack of a convenient animal model for infection and the fact that it
is unethical to perform human studies due to the risk of volunteers
developing GBS. Further, the self-limiting nature of C. jejuni-
mediated gastroenteritis in the majority with few requiring
hospitalisation, and the added risk of intestinal perforation severely
curtails the opportunity to investigate immunity to infection in situ.
In the present study we characterised the innate cytokine milieu
generated in response to C. jejuni in an ex-vivo model of infection,
which utilises human paediatric small intestine and colonic pinch
biopsies in the co-culture system. This in-vitro organ culture
(IVOC) system has been utilised extensively in investigating
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enteropathogenic E. coli (EPEC) infection [8] and work by Everest
and colleagues indicates it may also be suitable for studying C.
jejuni interactions with the human intestinal mucosa [9,10].
Dendritic cells (DC) are critical sentinel cells that relay microbial
presence either directly or indirectly (the latter via signals received
from the overlaying epithelial lining of the gut) to naı¨ve T cells; thus
instructing the adaptive immune system to mount an appropriate
response, which in a healthy host should promote successful
bacterial clearance while registering memory [11]. Several studies
have previously documented C. jejuni-mediated effects on murine
[12] and human [13,14] DC however, the impact of bacterial-DC
cross-talk on human T cell immunity remains less clear. Here, we
show that supernatants from C. jejuni-infected DC promoted
significant expansion of Th-17, Th-1 and Th-17/Th-1 double-
positive T cells. Collectively, our data highlights IFNc, IL-22 and
IL-17 family as critical mediators of host immunity both in the acute
and in the effector phase of C. jejuni infection.
Results
Ex-vivo colonisation of human intestine by C. jejuni
Prior to investigating host mucosal immunity to C. jejuni, it was
pertinent to establish if the bacteria were able to colonise the
human gut explant tissue in the IVOC model of infection. Biopsies
retained their 3-dimensional architecture over the 8–12 hour
experimental period. A representative confocal microscopic
visualisation of interaction between C. jejuni (green) and human
small intestine tissue (red) is shown in Figure 1. C. jejuni were
routinely found in close association with the epithelial lining
(Figure 1a), with particular propensity for micro-colony formation
while adhering to the small intestine (Figure 1b). Interestingly,
bacterial micro-colonies were not observed during co-culture with
colonic tissue (Zilbauer, M; unpublished observations).
Ex-vivo release of mucosal cytokines in response to C.
jejuni infection
We aimed to determine the mucosal cytokine milieu released in
response to C. jejuni with particular interest in cytokines implicated in
innate defence and those involved in T cell differentiation and
survival [15]. The majority of cytokines were undetectable or
minimally expressed in uninfected ileal (Figure 2a & b) and colonic
(Figure 2c & d) tissue during the 8 hour experimental time-period.
Amongst host defence cytokines tested, IFNc showed the most
significant induction in both ileal and colonic tissue [Figure 2a & 2c;
Ileal mean 251 pg/ml (SD 59.5); p = 0.0007; Colonic mean
271 pg/ml (SD 174.7); p = 0.0029]. IL-22 was secreted spontane-
ously by both the small and large intestinal tissue, suggesting a
potential role for this cytokine in maintaining tissue homeostasis.
Increase in ileal IL-22 expression was noted during infection
(88 pg/ml versus 108 pg/ml; p = 0.948) In comparison to IFNc and
IL-22, IL-17 induction was very modest [Figure 2b & 2d; Ileal mean
6.6 pg/ml (SD 2.3); p = 0.04; Colonic mean 7.4 pg/ml (SD 6.6);
p = 0.0042]. Amongst cytokines known to influence T-cell mediated
immunity, IL-23 showed the most significant increase [Ileal mean
54 pg/ml (SD 27.6); p = 0.0023; Colonic mean 53.5 pg/ml (SD
20.7); p = 0.0001]. IL-12 and IL-6 increase was intermediate with
IL-1b exhibiting a modest increase as noted for IL-17 protein levels.
C. jejuni wild-type strains drive an IL-23/IL-12 response in
monocyte-derived dendritic cells
To decipher the molecular nature of the T cell protective
immunity elicited in response to C. jejuni infection in humans, we
first investigated the effect of C. jejuni infection on DC cytokine
responses, with particular focus on IL-12 family members as they
are critical mediators in defining the molecular nature of
downstream T cell immunity. The IL-12 family members (IL-
12, IL-23, IL-27 & IL-35) share subunits [16] as p35 and p40
constitute IL-12, IL-23 comprises p19 & p40, IL-27 is a hetero-
dimer composed of p28 (a p35-related peptide) and Epstein-Barr
virus induced gene 3 (EBI3; a p40 related protein). EBI3 can also
associate with p35 to form IL-35. Further, p40 can also form
biologically active homo-dimers. DCs were exposed to both wild-
type (WT) C. jejuni 11168H (Figure 3) and 81–176 (data not shown)
strains and expression of the IL-12 family subunits investigated by
RT-PCR. In response to -C. jejuni infection, time-dependent
differential induction of the various subunits was seen amongst the
donors tested; this is highlighted in Figure S1. The majority of
individuals expressed p19, p35, p40 and EBI3 in response to
infection (Figure 3), however, amongst the donors tested, none
showed induction of the p28 subunit (n = 7; data not shown).
Figure 1. Ex-vivo colonisation of human intestine by C. jejuni. Human intestinal biopsies from the terminal ileum were co-cultured for 12 hrs
with WT C. jejuni 11168H. Following co-culture, bacteria were localized by immuno-labelling with primary unlabelled anti-campylobacter antibody
and secondary FITC labelled antibody (green). Actin filaments including apical brush border were visualized with rhodamine phalloidin (Red). TO-PRO
blue was used to counter-stain for nuclei (blue). Whole tissue samples were examined by confocal microscopy. Transverse cross-section of the tissue
(a) and an apical view (b) are shown.
doi:10.1371/journal.pone.0015398.g001
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The cytokine responses were quantified by ELISA (Figure 4).
IL-12, IL-23, IL-1b and IL-6 were undetectable in DCs exposed to
medium alone. In contrast, all 4 cytokines were induced in the
presence of WT C. jejuni infection. Interestingly, the majority of
donors showed a greater propensity for IL-23 production
compared to IL-12 (Figure 4). Due to the lack of commercially
available antibodies against human IL-27 and IL-35 these
cytokines were not quantified at protein level. Co-expression of
p35 and EBI3 observed 8 hours post-infection however, does not
preclude IL-35 expression.
C. jejuni- infected DCs generate a cytokine milieu that
favours single Th-17, Th-1 and double Th-17/Th-1
positive T cell responses
In the present study we focused on elucidating the impact of
‘live’ C. jejuni infection on innate and adaptive T-cell responses.
The ‘live’ nature of the infection inherently prohibited us from
performing standard bacterial-DC-T cell co-culture studies. DC-T
cellular interactions are critical for determining T-cell proliferative
capacity; the cytokine milieu generated in contrast has a major
impact on T cell effector function [15]. We tested the ability of
supernatants (filter-sterilised to remove live bacteria) from infected
DCs (from donors shown in Figure 4) to propagate
CD4+CD45RO+ T cell effector responses. Flow cytometric
analysis of intracellular IFNc and IL-17A staining showed an
increase in single-positive IL-17A and IFNc cells and a preferential
increase in IL-17A/IFNc double-positive cells. A representative
plot is shown in Figure 5a. Collectively, C. jejuni-infected DC
supernatants tested showed a significant increase in IL-17A/IFN-c
double-positive (P = 0.004), single IL-17A (P = 0.04) and single
IFN-c (P = 0.01) producing T cells (Figure 5b). Increase in IFN-c
and IL-17 protein was confirmed by ELISA (n = 4 donors;
Figure 5c). Taken together, the data indicated that C. jejuni-
infected DC cytokine milieu had the ability to amplify both Th17
and Th1 responses.
Figure 2. Ex-vivo mucosal cytokine responses to C. jejuni 11168H infection. Paediatric (a) terminal ileum and (b) colonic biopsy tissue were
exposed to WT C. jejuni 11168H strain (16109/ml) bacteria for 8 hours. Post-infection IFNc and IL-22 (a & c) and IL-17, IL-12, IL-23, IL-1b and IL-6 (b & d)
protein were quantified (Data shown with median).
doi:10.1371/journal.pone.0015398.g002
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T-cell derived IL-22 expression in response to C. jejuni
infection
In addition to innate immune cells being a source of IL-22
[17,18], its expression is also associated with Th-1 [19], Th-17
[20] and a distinct Th-22-cell sub-type [21], indicating widespread
expression of IL-22 can occur in the intestinal mucosa. We
therefore investigated if C. jejuni infection resulted in T-effector
cells secreting IL-22. T-cell mediated IL-22 expression was indeed
observed in the presence of infected DC supernatants [mean
3279 pg/ml (SD 1392) p = 0.0275; Figure 5c]. Interestingly, much
more modest amounts of IL-22 (mean 18 pg/ml; data not shown)
were also detected in the DC milieu itself, which did not show a
significant change in response to infection.
IL-17A and F modulate number of intracellular C. jejuni in
intestinal epithelia
The generation of the mucosal, innate IFNc/IL-22/IL-17
cytokine triad and Th-17/Th1 dual immunity with IL-22 secreting
ability in response to C. jejuni infection suggested a critical role for
these cytokines in eliciting antimicrobial immunity to C. jejuni. We
hypothesised that in addition to their well-established bactericidal
and tissue repair functions [15,18] this triad may modulate C. jejuni
adhesion and invasion to intestinal epithelial cells (IEC). To test
this hypothesis, polarised Caco-2 cells were incubated with IFNc,
IL-17A, IL-17F or IL-22 for 24 hours (to activate cytokine-
mediated IEC bactericidal cellular events) prior to exposure to
C. jejuni at an MOI = 100. 3 hours post-infection a standard
bacterial adhesion and invasion assay was performed. None of the
cytokines were able to modify the number of C. jejuni 11168H
bacterial cells that adhered to IEC (Figure 6a). Pre-treatment with
IFNc or IL-22 had minimal effect on the number of viable
intracellular bacteria. In contrast, IL-17A and in particular IL-17F
significantly reduced the number of viable intracellular bacteria
(Figure 6b).
Discussion
Globally, morbidity and mortality in children due to diarrhoeal
infectious disease(s) still remains a major challenge. Amongst
known human enteropathogens, determination of the molecular
pathogenesis of disease in C. jejuni enteritis has proven problematic
for several reasons. Firstly, the possibility of generation of
autoimmune antibodies due to molecular mimicry between
C. jejuni sialylated LOS and host gangliosides as observed with
GBS [4] curtails the feasibility of human volunteer studies.
Secondly, the availability of a convenient small animal model that
recapitulates human intestinal pathology has been limiting to date
[22–24]. Thirdly, and most importantly, the paucity of informa-
tion with regard to how the GI mucosa senses C. jejuni leading to
protective immunity remains a major stumbling block towards our
current understanding of C. jejuni-mediated disease pathogenesis.
In the present study we established that the IVOC model system
utilising human gut explant tissue can serve as a viable model to
investigate early host immunity to C. jejuni. The maintenance of
tissue viability and architectural integrity over the 12 hour-co-
culture period (Figure 1) added credence to the mucosal cytokine
responses obtained (Figure 2). It was interesting to note that
Figure 3. Monocyte-derived DC (DC) cytokine milieu in response to C. jejuni 11168H wild-type strain. DCs incubated in media alone
served as Control (C) or were infected with C. jejuni 11168H wild-type (WT) strain (multiplicity of infection; MOI = 100). mRNA expression of the IL-12
family members (p19, p35, p40, EBI3 at 8 and 24 hours) was quantified by RT-PCR. (a) Gene expression was normalised to GAPDH. Variations in mRNA
levels are expressed as fold induction compared to the uninfected control cells. (Median is shown). A representative gel to highlight variation in
subunit expression between donors (D) is included (see Figure S1).
doi:10.1371/journal.pone.0015398.g003
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C. jejuni micro-colonies were frequently found to adhere to the
small intestine; this was rarely observed with colonic tissue.
Haddock and colleagues have recently reported similar findings
[10]. point to note however, is that despite the lack of micro-
colony formation on colonic tissue, the magnitude of cytokine
response(s) elicited by the small and large intestine were found to
be similar (Figure 2). Future studies must address how the GI tract
senses, interacts and responds to the various guises (i.e. single cell,
micro-colony and/or biofilms) that C. jejuni can adapt to [10,25].
Analysis of mucosal immunity to C. jejuni allows us to
hypothesise a critical role for IFNc in particular, during the early,
acute phase of infection (Figure 2a & c). Spontaneous, basal IL-22
secretion and ileal IL-22 induction post-infection are also worth
noting. Both cytokines exert potent epithelial bactericidal and
repair functions [18,26]. These include enhanced production of
epithelial b-defensins, which we have shown previously to be
effective antimicrobials against C. jejuni [27]. IL-17A is also an
agonist for b-defensin production [28]. In comparison to IFNc
and IL-22 however, IL-17A expression in response to C. jejuni was
very modest (Figure 2b & d). One may speculate that IL-17A levels
found maybe are sufficient in contributing to the ‘protective’
antimicrobial shield exerted by IFNc and IL-22. The pathological
effects of high IL-17 leading to ‘autoimmune reactivity’ are well-
established [15,29,30] making tight regulation of IL-17 expression
during infection a desirable option.
Currently the identity of mucosal cell type(s) that contribute to
innate cytokine production during GI infection(s) in humans
remains largely unknown. Many mucosal cell phenotypes
including Natural Killer (NK) cells, CD8 and cd T cells have
the capacity to secrete IFNc [31]. We found monocyte-derived
DC to be low IL-22 secretors (data not shown) and this cell-type
could potentially contribute to the observed mucosal IL-22
expression. A subset of NK cells; NKp46+ cells are known IL-22
producers and could also be a likely source [17,32]. Mucosal
lymphoid tissue inducer (LTi) cells can secrete both IL-22 and IL-
17 and are, therefore, another potential candidate cell-type [32].
Greater availability of human reagents in the near future should
greatly aid in resolving the identity of the cell-types involved.
Accumulating evidence indicates that IL-23 is a likely master
regulator of mucosal immunity during GI infection and inflamma-
tion [33]. We observed mucosal (Figure 2) and DC (Figure 4)
production of IL-23 in response to C. jejuni. In the majority of
participants mucosal and DC-derived IL-12 and IL-23 were
undetectable in the absence of the stimuli, upon infection however,
most individuals showed a robust IL-23 response compared to IL-12
(Figure 4). IL-23 is a pleiotropic cytokine; it’s role as a major survival
factor for IL-23 receptor expressing Th-17 cells is well characterised
[15]; in addition, an increasing body of emerging data indicates that
IL-23 can amplify and expand Th-17 independent IL-17A and IL-
22 production [29,34]. Cecal IL-23 is a major stimulus for IL-17/
IL-22 expression by cd T cells during Salmonella enterica serotype
Typhimurium infection in streptomycin-treated mice [35]. It would
be interesting to investigate if this IL-23-mediated IL-17/IL-22
immunity occurs in human infections.
Figure 4. C. jejuni 11168H wild-type strain modulates expression of a panel of DC-derived cytokines implicated in human T cell
differentiation and survival. DCs from donors were exposed to WT C. jejuni 11168H wild-type strain or E. coli LPS (10 mg/ml) for 24 hours and
cytokine levels measured by ELISA. Significant increase in (a) IL-1b, (b) IL-6, (c) IL-12 and (d) IL-23 protein levels was noted (median is shown).
doi:10.1371/journal.pone.0015398.g004
Mucosal Innate and T-Cell Immunity to C. jejuni
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15398
At present, the cellular source of mucosal IL-23 observed in our
ex-vivo model system is unknown. A unique subset of CD14+
macrophages found in ‘inflamed’ human intestine has been
identified as a source of IL-23 [36]. Mucosal cell-phenotypes such
as the Paneth cell of the small intestine [37] and a novel innate
Thy1+, ROR-ct-transcription factor expressing lymphoid cell type
[33] are novel ‘potential’ candidate cells that may secrete IL-23 in
response to noxious stimuli. Clearly more studies are warranted to
delineate the role and contribution of the various innate cell-types
to IL-23 expression during GI infection and inflammation. On the
latter note, a recent epidemiological study involving 13,148 IBD
patients found a significant increase in disease incidence in
individuals who were exposed to Salmonella/Campylobacter gastro-
enteritis in the previous year [3]. In addition, variants of IL-23
receptor are linked to susceptibility to IBD [38]. Collectively, data
suggests a role for IL-23 not only in C. jejuni-mediated host
immunity, but it may also prove pivotal in modulating
susceptibility to IBD post-C. jejuni gastroenteritis.
Figure 5. C. jejuni 11168H infected-DC supernatants promote expansion of Th-17/Th-1 immunity. PBMCs were enriched for
CD4+CD45RO+ memory T cells and stimulated with anti-CD3, anti-CD28 coated beads for 5 days in the presence of supernatants taken from DCs
cultured with medium only or with C. jejuni 11168H WT strain. (a) A representative flow cytometric plot of cultured T cells, stimulated with PMA and
ionomycin for 3 hours in the presence of Brefeldin A and stained for intracellular IL-17A and IFNc is shown. (left panel; T cells cultured in uninfected
DC supernatants, right panel; T cells cultured in C. jejuni-infected DC supernatants). (b) Number of IL-17+IFNc+ (left), IL-17+IFNc2 (middle) and
IFNc+IL-172 (right) cells as a percentage of CD4+ T cells, as in (a), n = 7. (c) T-cell derived cytokine [IFN-c (n = 4; left), IL-17 (n = 4; middle) and IL-22
(n = 6; right),] protein quantified 5 days post-stimulation.
doi:10.1371/journal.pone.0015398.g005
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In order to gain better insight into how the DC cytokine milieu
generated in response to live C. jejuni infection dictates cellular
immunity, T cells were cultured in the presence of infected-DC
supernatants obtained from various donors. A propensity for
expansion of single Th-17, single Th-1 and double-positive Th17/
1 cells was noted (Figure 5). Recently Lee and colleagues have shed
light on the molecular nature of IL-17/IFN-c double-positive cells
[39]. Th-17 cells undergo plasticity towards a Th17/1 phenotype
by up-regulating IFNc in response to IL-12 or IL-23 in the
absence of TGF-b. IL-17 expression may be completely
extinguished such that Th-17 cells develop a Th-1 phenotype,
though in humans, expression of the Th-17 marker CD161 is
maintained on these ‘‘converted’’ cells [40]. This plasticity of Th-
17 cells may be particularly important in mounting immunity
against mucosal pathogens that can reside in different niches, i.e.,
remain extracellular and yet exhibit ‘invasive’ properties.
The present study implicated an innate IFNc/IL-22/IL-17 and
an adaptive Th-17/Th-1 dual response to C. jejuni; suggesting this
cytokine triad may represent an adequate ‘antimicrobial shield’ that
promotes bacterial clearance and generation of protective immu-
nity. IL-17A and –F can homo- or hetero-dimerise and each iso-
form shows distinct efficacy [41,42]. Early neutrophil recruitment,
granulocyte colony stimulatory factor, macrophage-inflammatory
protein-2 and antimicrobial peptide production at the site of
infection are critical functions assigned to IL-17 as lack of these
responses increases systemic bacterial dissemination reducing
overall survival [17,30,42]. Antimicrobial peptides exert their effects
on microbes in multiple ways. In addition to direct bactericidal
action, they can also modulate the rate of bacterial uptake by host
innate cells [43]. We wished to know if IFNc/IL-22 and IL-17-
mediated activation of IEC exerted any effect on C. jejuni adhesion
and invasion. IFNc and IL-22 activation had minimal effect on
C. jejuni adhesion or intracellular survival. In contrast, we clearly
observed IL-17 mediated effects on the number of intracellular
bacterial cells in IEC (Figure 6b). IL-17 family members can directly
induce human b-defensin 2 (hBD-2) [28]; whether hBD-2 is
responsible for reduced bacterial numbers or additional bactericidal
signalling events promote this protection remains to be determined.
In conclusion, IFNc, IL-22 and IL-17 family represent the
cytokine triad that is likely to be protective both in the acute and
effector(s) phase of C. jejuni infection. In addition to the
antimicrobial spectrum exerted by the trio, IL-17A and –F may
enhance mucosal immunity by modulating C. jejuni invasion and
survival within IEC. A recent study showed that C. jejuni can
survive within IEC by avoiding delivery to lysosomes [44]. This
indicates that C. jejuni has evolved specific immune evasion
strategies; manipulation of host mucosal immunity to counteract
the evasion strategies is a future therapeutic challenge. Further,
understanding how this ‘protective’ cytokine triad turns patholog-
ical will not only aid in better vaccine design for infectious
gastroenteritis, but may also improve our understanding of how
bacteria trigger and cause relapse in IBD.
Materials and Methods
In-Vitro Organ Culture (IVOC)
Intestinal biopsies were cultured as described previously [45]. 11
males and 8 females were recruited to the study (median age; 11
years). Tissue samples were microscopically examined and only
intact, non-haemorrhagic tissue (orientated with mucosal surface
facing upwards) was incubated in 12-well plates containing 1.0 ml
of pre-warmed (37uC) IVOC medium on a rocking platform at
37uC in 95% O2/5% CO2 in a humidified incubator for 8 hours.
The explant was inoculated with 16109 colony forming units (cfu)
of C. jejuni 11168H or 81–176. The IVOC medium was replaced
after 4 hours, to maintain pH and nutrient levels, and the tissue re-
inoculated with bacteria as before.
Confocal microscopy of human small bowel biopsies
Human intestinal biopsies from the terminal ileum were co-
cultured, as described above, for 12 hrs with apical addition of
WT C. jejuni 11168H. Uninfected tissue served as control (data not
shown). Post-infection, tissue explants were washed 3 times in fresh
IVOC media (to remove non-adherent bacteria) and fixed in 4%
PFA. Tissue was permeablised by immersion in 0.2% Triton-X/
PBS (Sigma, Poole, UK) for 5 min at RT. Non-specific binding
Figure 6. IL-17A and IL-17F reduce C. jejuni 11168H intracellular survival in intestinal epithelia. Confluent Caco-2 cells were exposed to
individual cytokines for 24 hours prior to infection with C. jejuni 11168H WT strain (MOI = 100) for 3 hours at 37uC. Cell lysates were serially diluted
and plated for total viable bacterial counts (adhesion + invasion). In parallel, another set of infected cells was exposed to 150 mg/ml gentamicin for
2 hours (to kill extracellular adhered bacteria) and lysates plated for enumeration of viable intracellular bacteria. Data represent average percentage
cfu obtained in treated versus untreated cells (the latter set at 100%). Statistical analysis of 3 independent experiments performed in duplicate is
shown versus untreated cells (Data shown as the median + range).
doi:10.1371/journal.pone.0015398.g006
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was blocked by incubation in 1% BSA/PBS for 45 min.
Subsequently, bacteria were localized by utilising a goat anti-
campylobacter antibody (5 mg/ml; KPL, Maryland, USA) for 60 min
at RT. After washing, tissue was incubated with FITC-conjugated
rabbit anti-goat (0.5 mg/ml; Molecular probes, Eugene, Oregon,
USA) secondary antibody for 30 min. Actin cytoskeleton and
nuclei were stained with rhodamine phalloidin (1unit/ml in PBS/
BSA; Invitrogen, Paisley, UK) for 45 min and TO-PRO blue
(Molecular Probes, Euegene, Oregon, USA) for 30 min respec-
tively. Finally, whole biopsies were mounted in Vectashield
(Vector Laboratories Ltd) and visualized with a radiance 2100
confocal laser scanning microscope equipped with an argon-
krypton laser and a red diode (Bio Rad Labs).
Generation of monocyte-derived DC from Peripheral
Blood Mononuclear cells (PBMC)
Monocyte-derived dendritic cells (DC) were generated as
described previously [46]. Briefly, PBMC were collected from
healthy donors by density centrifugation (Axis Shields, Uxbridge
UK). 16106 PBMC were cultured in RPMI supplemented with
5% (v/v) human AB serum (Sigma, Poole, UK) supplemented with
100 and 50 ng/ml human recombinant GM-CSF and IL-4 (R &
D, Abingdon, UK) respectively, at 37uC/5% CO2 for 6 days.
Immature DCs were CD3-negative, CD14-low, CD19-negative,
CD83-negative, CD25-negative and expressed low levels of HLA-
DR, HLA-DQ, HLA-Class 1, CD40, CD86 and CD1.
C. jejuni/DC co-culture
C. jejuni 11168H and 81–176 wild-type (WT) strains were
employed. C. jejuni 11168H is a hyper-motile derivative of the
genome sequenced NCTC11168 strain, which shows much higher
colonisation levels in a chick colonisation model [47] and is thus
considered the better strain to use for host-pathogen interaction
studies. Strains were routinely cultured at 37uC for 24 hours on
Columbia agar (Oxoid, Basingstoke, UK) plates supplemented
with 7% (v/v) defibrinated horse blood (TCS Microbiology,
Botolph Calydon, UK) and Campylobacter selective supplement
(Skirrow; Oxoid) in a micro-aerobic chamber (Don Whitley
Scientific Ltd, Shipley, UK) containing 85% N2, 5% O2 and 10%
CO2. 1610
6 PBMC were exposed to WT C. jejuni at a multiplicity
of infection (MOI) of 100; or to E. coli LPS 10 mg/ml (Sigma,
Poole, UK), for 8 or 24 hours prior to analysis.
Cytokine specific gene and protein expression
Following infection, DC or biopsies were subjected to RNA
extraction utilising TRIZOL followed by cDNA synthesis
(Invitrogen, Paisley, UK) and polymerase chain reaction (PCR;
Bioline, London, UK). See Table S1 for specific cytokines tested.
Human IL-12 (p70), IL-23, IL-1b, IL-6, IL-17A, IFN-c and IL-
22 were measured in control, uninfected and infected DC, T cell
and in biopsy supernatants using commercial ELISA kits
(eBioscience, Hatfield, UK and R & D, Abingdon, UK).
T-cell responses to C. jejuni-infected DC supernatants
CD4+CD45RO+ T cells were purified from healthy PBMC by
magnetic bead based negative selection (Stem cell technologies,
Grenoble, France). Purified T cells were cultured for 5 days with
DC-derived supernatants diluted with RPMI supplemented with
5% (v/v) FCS in the presence of anti-CD3, anti-CD28 coated
micro-beads (Milteyni Biotec, Surrey, UK). T cell supernatants
were harvested and IFN-c, IL-17A and IL-22 protein levels were
quantified by ELISA. For intracellular cytokine analysis, T cells
were harvested on day 5 and cultured for 3 hours in the presence
of 50 ng/ml Phorbol Myristate Acetate (PMA), 500 ng/ml
ionomycin, and 5 mg/ml Brefeldin A. Prior to antibody staining
cells were first fixed in 4% (v/v) PFA in PBS and permeabilized in
0.1% (w/v) saponin. All reagents utilized were from Sigma, Poole,
UK. Antibodies and wash buffer also contained 0.1% (w/v)
saponin [48]. Phycoerythrin-Cyanin 7-labelled CD4, FITC-
labeled IFN-c (BD PharMingen, Oxford, UK), Alexa Fluor 647–
labeled IL-17A (eBioscience, Hatfield, UK), and PE-labeled IL-22
(R&D, Abingdon, UK) were utilized. 100,000 to 200,000 events
were collected with a Cyan ADP flow cytometer (Dako,
Cambridgeshire, UK); for each condition, and cells were gated
by their light scatter properties. Data were analyzed using FlowJo
software (Tree Star, Ashland, OR).
Gentamicin protection assay
The ability of C. jejuni 11168H to adhere to and invade IEC was
tested on Caco-2 cells, (a human colorectal cancer cell-line) as
detailed previously [49]. Caco-2 cells were exposed to 100 ng/ml
IFN-c or IL-17A, IL-17F or IL-22 (Peprotech, London, UK) for
24 hours before 16108 cfu of WT C. jejuni 11168H were added.
Adhesion was allowed to proceed for 3 hours at 37uC. Cells were
washed three times in PBS before cell lysis [2% (v/v) Triton-X100
in PBS; 15 minutes at 37uC]. Serial dilutions were plated onto
blood agar plates for viable bacterial counting. For quantification
of intracellular bacteria, cells were washed and incubated with
150 mg/ml gentamicin (Sigma, Poole, UK) for an additional
2 hours before proceeding with cell lysis and plating.
Statistical Analysis
Statistical analyses were performed using GraphPad Prisim 4.
Differences in gene or protein expression between control un-
stimulated cells and stimulus (which will be denoted as * on
reaching statistical significance) were evaluated using a two-tailed
Mann-Whitney U-test. A p value of ,0.05 was considered
statistically significant (* p#0.05 ** p#0.01 *** p#0.001).
Ethics statement
Ethical approval for obtaining intestinal mucosal biopsies from
patients undergoing routine endoscopic procedure was granted by
the Institute of Child Health/Great Ormond Street Hospital
Research Ethics Committee (06/Q0508/26). The biopsies were
taken under the direction of the clinician in charge after fully
informed parental consent was obtained.
Blood samples from Healthy volunteers were also obtained with
informed consent and ethical approval from the Institute of
Child Health/Great Ormond Street Hospital Research Ethics
Committee.
Supporting Information
Figure S1 Monocyte-derived DC (DC) cytokine milieu
in response to C. jejuni 11168H wild-type strain. DCs
incubated in media alone served as Control (C) or were infected
with C. jejuni 11168H wild-type (WT) strain (multiplicity of
infection; MOI = 100). mRNA expression of the IL-12 family
members (p19, p35, p40, EBI3 at 8 and 24 hours) was quantified
by RT-PCR. Shown is a representative gel to highlight variation in
subunit expression between donors (D). (TIF)
Table S1 Primers used in this study. (DOC)
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